Webinar - How High Level Disinfectants are Tested to Inactivate Human Papillomaviruses - HPV

WEBINAR

Learning Objectives

  • What are the HPV cross-contamination risk in ultrasound
  • What are the different HPV research test protocols
  • How HPV research supports clinical change in ultrasound probe reprocessing

Dr. Meyers has done extensive research in HPV

  • We have studied how different strains of HPV causes cancer, especially high risk HPV16 and HPV18
  • We were the first lab to develop a technique to grow natural High Risk HPV that causes >90% of cervical cancer and >60% at other anogenital cancers and are responsible for a significant portion of oropharyngeal cancers:1-6
  • We have worked on growing HR HPV for over 35 years, and know how the virus needs to mature and be structurally stable. The HPV test is based on the ASTM E1053-11 standard test method suitable for assessing virucidal activity on non-porous surfaces . This standard meets requirements for virucides, which are in turn referenced by the FDA for 510(k) submissions for high-level disinfectants.
  •  
  1. Meyers J, Ryndock E, Conway MJ, Meyers C, Robison R. Susceptibility of high-risk human papillomavirus type 16 to clinical disinfectants. J Antimicrob Chemother. 2014;69(6):1546-50.
  2. Meyers C, Milici J, Robison R (2017) UVC radiation as an effective disinfectant method to inactivate human papillomaviruses. PLoS ONE 12 (10): e0187377.
  3. Maxime Pichon, Karine LebailCarval, Geneviève Billaud, Bruno Lina, Pascal Gaucherand and Yahia Mekki (2019) Decontamination of Intravaginal Probes Infected by Human Papillomavirus (HPV) Using UV-C Decontamination System. J. Clin. Med, 8, 1776; doi:10.3390/jcm8111776.
  4. https://www.iarc.who.int/infographics/cervical-cancer-awareness-month-2021/
  5. Saraiya, M., Unger, E., Thompson, T., Lynch, C., Hernandez, B., Lyu, C., Steinau, M., Watson, M., Wilkinson, E., Hopenhayn, C., Copeland, G., Cozen, W., Peters, E., Huang, Y., Saber, M., Altekruse, S. and Goodman, M. (2016). US Assessment of HPV Types in Cancers: Implications for Current and 9-Valent HPV Vaccines.
  6. Tota et al. (2011) Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies. Prev Med. 53 Suppl 1: S12-21.
Scroll to Top